Journal of Clinical Oncology
Articles in this Issue
Trends in kidney cancer: Exploring the impact of sex and age on stage of disease, and prognosis during the past three decades in Denmark—A DaRenCa study.
485 Background: Over the past 30 years, renal cell carcinoma (RCC) management has undergone significant advancements, driven by increased diagnosis throug...
Targeting TROP2 in aggressive variant and neuroendocrine prostate cancer.
171 Background: Aggressive variant prostate cancer (AVPC) including neuroendocrine prostate cancer (NEPC) is characterized by rapid, androgen-independent...
Observational study of tislelizumab (Tisle) combined with pazopanib in reducing venous tumor thrombus in clear cell renal cell carcinoma with venous invasion.
481 Background: Renal cell carcinoma with venous tumor thrombus (RCC-VTT) presents significant surgical challenges, often requiring complex interventions....
Avelumab first-line (1L) maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Updated real-world results from a national reimbursement registry.
693 Background: Platinum-based chemotherapy followed by avelumab 1L maintenance treatment for patients with nonprogressive disease is a standard of care i...
Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies.
501 Background: Since its approval, PD-1/PD-L1 IO therapies are used greatly among patients with mRCC. However, outcomes in the post-IO setting are not we...
Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.
437 Background: CheckMate 214 established nivolumab and ipilimumab (NIVO+IPI) as a first line standard of care regimen with superior survival and durable...
A heterologous prime-boost strategy using RUTI vaccine to improve the BCG response in non–muscle-invasive bladder cancer patients (RUTIVAC-1 trial).
801 Background: Despite standard-of-care therapy with transurethral resection of bladder tumor and intravesical BCG instillation, a significant percentage...
Novel urine-enriched RNA panel (EPCAM, TTC3, H4C5) to detect prostate cancer and differentiate it from benign prostatic disease.
31 Background: Prostate Cancer (PCa) is one of the leading causes of cancer deaths among men worldwide. Although the Prostate-Specific Antigen (PSA) test...
Real-world prevalence and outcomes of androgen receptor ligand-binding domain mutations in prostate cancer.
93 Background: Anti-hormonal therapies targeting the androgen receptor (AR) pathway are the standard of care treatment for patients with prostate cancer (...
Association between clonal hematopoiesis and survival after nephrectomy in patients with renal cell carcinoma.
589 Background: Clonal hematopoiesis of indeterminate potential (CH) is an age-related phenomenon marked by the clonal expansion of hematopoietic stem cel...
Impact of prior primary care utilization on limiting racial disparities for prostate cancer diagnosis and mortality.
26 Background: Black men are more likely to develop lethal prostate cancer (PCa) than non-Hispanic White men. It is not clear if this disparity is related...
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).
552 Background: Substudy 03B of the phase 1/2 KEYMAKER-U03 trial (NCT04626518) was designed to evaluate combination treatments with pembro and investigati...
Checkpoint blockade as neoadjuvant strategy: A single-arm meta-analysis of dual PD-1/PD-L1 and CTLA-4 inhibition in urothelial cancer.
783 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the standard treatment for muscle-invasive urothelial can...
Patient perceptions about their treatment for muscle-invasive bladder cancer (MIBC) over the last decade.
765 Background: The Bladder Cancer Advocacy Network (BCAN) is a national patient advocacy organization that has promoted awareness about the signs, sympto...
Association between molecular changes and perioperative immunotherapy in patients with advanced clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
573 Background: Immunotherapy (IO) combinations are standard first-line treatments for advanced clear cell renal cell carcinoma (ccRCC). However, identify...
Outcomes for <sup>177</sup> Lu-PSMA-617 with and without concurrent use of ARPIs in patients with mCRPC.
112 Background: We now have more than a decade of experience using Androgen Receptor Pathway Inhibitors (ARPIs) across various disease states of prostate...
Use and clinical outcomes of androgen receptor inhibitors (ARIs) for non-metastatic castration resistant prostate cancer (nmCRPC) at labeled doses in Japan.
170 Background: The androgen receptor inhibitors (ARIs) darolutamide (DAR), enzalutamide (ENZ), and apalutamide (APA) are recommended for treatment of nmC...
Evaluation of systemic therapy and surgical consolidation in patients with node positive upper tract urothelial carcinoma.
816 Background: The recommended treatment for high-grade upper tract urothelial carcinoma (UTUC) includes radical nephroureterectomy with regional lymph n...
Understanding metastatic squamous cell carcinoma patients receiving pelvic exenteration vs radical cystectomy: A nationwide context.
681 Background: Squamous Cell Carcinoma (SCC) is a rare subtype of bladder cancers, consisting of 2-5% of all bladder cancers. SCC is associated with chro...
Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177-PSMA-617 (Lu) based on line of therapy.
82 Background: Lu is a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical that delivers beta radiation to PSMA-positive cells. It is a...
Additivity and the efficacy of immune checkpoint blockade-based combination regimens in urothelial cancer.
779 Background: Immune checkpoint blockade (ICB)-based combination regimens have transformed the treatment landscape of advanced solid tumors including ur...
Evaluating associations between genomic classifier and digital pathology–based multi-modal AI biomarkers in oligometastatic castration-sensitive prostate cancer.
231 Background: Prostate cancer is a heterogeneous disease ranging from indolent localized to metastatic castration-resistance. Efforts to generate progno...
Can magnetic resonance imaging safely replace a confirmatory biopsy in patients on active surveillance for prostate cancer?
331 Background: Active surveillance (AS) is recognized as the preferred management for patients with low-risk prostate cancer, and many with favorable int...
Ethnic disparities in clinical trials for FDA-approved drugs in prostate cancer: A post–COVID-19 era analysis (2020-2024).
25 Background: It is known that ethnic and racial inequality in participation in oncology clinical trial is a contemporary problem. Efforts have been made...
Development of an ex-vivo platform to model immunotherapy in kidney cancer.
592 Background: The treatment landscape for metastatic clear cell renal cell carcinoma (mccRCC) has evolved, with immune checkpoint inhibitor (ICIs) combi...